Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163996220> ?p ?o ?g. }
- W3163996220 endingPage "2639" @default.
- W3163996220 startingPage "2639" @default.
- W3163996220 abstract "Despite the improvement in survival outcomes, multiple myeloma (MM) remains an incurable disease. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) represents a new strategy for the treatment of relapsed/refractory MM (R/R). In this paper, we describe several recent advances in the field of anti-BCMA CAR T-cell therapy and MM. Currently, available data on anti-BCMA CART-cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated R/R MM patients. Despite this, the main issues remain to be addressed. First of all, a significant proportion of patients eventually relapse. The potential strategy to prevent relapse includes sequential or combined infusion with CAR T-cells against targets other than BCMA, CAR T-cells with novel dual-targeting vector design, and BCMA expression upregulation. Another dark side of CART therapy is safety. Cytokine release syndrome (CRS) andneurologic toxicity are well-described adverse effects. In the MM trials, most CRS events tended to be grade 1 or 2, with fewer patients experiencing grade 3 or higher. Another critical point is the extended timeline of the manufacturing process. Allo-CARs offers the potential for scalable manufacturing for on-demand treatment with shorter waiting days. Another issue is undoubtedly going to be access to this therapy. Currently, only a few academic centers can perform these procedures. Recognizing these issues, the excellent response with BCMA-targeted CAR T-cell therapy makes it a treatment strategy of great promise." @default.
- W3163996220 created "2021-06-07" @default.
- W3163996220 creator A5012566344 @default.
- W3163996220 creator A5019004022 @default.
- W3163996220 creator A5025049786 @default.
- W3163996220 creator A5025476428 @default.
- W3163996220 creator A5041172440 @default.
- W3163996220 creator A5042364382 @default.
- W3163996220 creator A5051391019 @default.
- W3163996220 creator A5054016975 @default.
- W3163996220 creator A5055190032 @default.
- W3163996220 creator A5057185131 @default.
- W3163996220 creator A5062082063 @default.
- W3163996220 creator A5067216825 @default.
- W3163996220 creator A5073761054 @default.
- W3163996220 creator A5083968415 @default.
- W3163996220 creator A5086116060 @default.
- W3163996220 creator A5088055048 @default.
- W3163996220 creator A5089025495 @default.
- W3163996220 date "2021-05-27" @default.
- W3163996220 modified "2023-10-16" @default.
- W3163996220 title "CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma" @default.
- W3163996220 cites W1991494425 @default.
- W3163996220 cites W2153147430 @default.
- W3163996220 cites W2592857667 @default.
- W3163996220 cites W2602750734 @default.
- W3163996220 cites W2619886251 @default.
- W3163996220 cites W2620479671 @default.
- W3163996220 cites W2755114342 @default.
- W3163996220 cites W2783481538 @default.
- W3163996220 cites W2795246883 @default.
- W3163996220 cites W2801641802 @default.
- W3163996220 cites W2807637103 @default.
- W3163996220 cites W2818540548 @default.
- W3163996220 cites W2899318000 @default.
- W3163996220 cites W2899403047 @default.
- W3163996220 cites W2901323206 @default.
- W3163996220 cites W2903941856 @default.
- W3163996220 cites W2921533600 @default.
- W3163996220 cites W2923396001 @default.
- W3163996220 cites W2924578117 @default.
- W3163996220 cites W2956329092 @default.
- W3163996220 cites W2984531044 @default.
- W3163996220 cites W2984594015 @default.
- W3163996220 cites W2987545176 @default.
- W3163996220 cites W2987933200 @default.
- W3163996220 cites W2989809912 @default.
- W3163996220 cites W3000223620 @default.
- W3163996220 cites W3013052141 @default.
- W3163996220 cites W3028760088 @default.
- W3163996220 cites W3031337047 @default.
- W3163996220 cites W3032142108 @default.
- W3163996220 cites W3033351565 @default.
- W3163996220 cites W3040437182 @default.
- W3163996220 cites W3045978511 @default.
- W3163996220 cites W3048466779 @default.
- W3163996220 cites W3080714131 @default.
- W3163996220 cites W3082666946 @default.
- W3163996220 cites W3083502363 @default.
- W3163996220 cites W3087621471 @default.
- W3163996220 cites W3087735636 @default.
- W3163996220 cites W3091008757 @default.
- W3163996220 cites W3092706317 @default.
- W3163996220 cites W3095060432 @default.
- W3163996220 cites W3095078289 @default.
- W3163996220 cites W3096172173 @default.
- W3163996220 cites W3096209814 @default.
- W3163996220 cites W3096273414 @default.
- W3163996220 cites W3097165087 @default.
- W3163996220 cites W3097418661 @default.
- W3163996220 cites W3097651943 @default.
- W3163996220 cites W3097902874 @default.
- W3163996220 cites W3097912792 @default.
- W3163996220 cites W3101609280 @default.
- W3163996220 cites W3106597020 @default.
- W3163996220 cites W3106753232 @default.
- W3163996220 cites W3108588346 @default.
- W3163996220 cites W3109405061 @default.
- W3163996220 cites W3111462718 @default.
- W3163996220 cites W3111720937 @default.
- W3163996220 cites W3112088296 @default.
- W3163996220 cites W3115813616 @default.
- W3163996220 cites W3115931723 @default.
- W3163996220 cites W3116235698 @default.
- W3163996220 cites W3117741304 @default.
- W3163996220 doi "https://doi.org/10.3390/cancers13112639" @default.
- W3163996220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8197914" @default.
- W3163996220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34072068" @default.
- W3163996220 hasPublicationYear "2021" @default.
- W3163996220 type Work @default.
- W3163996220 sameAs 3163996220 @default.
- W3163996220 citedByCount "15" @default.
- W3163996220 countsByYear W31639962202021 @default.
- W3163996220 countsByYear W31639962202022 @default.
- W3163996220 countsByYear W31639962202023 @default.
- W3163996220 crossrefType "journal-article" @default.
- W3163996220 hasAuthorship W3163996220A5012566344 @default.
- W3163996220 hasAuthorship W3163996220A5019004022 @default.